Ocular Therapeutix, Inc.: Ocular Therapeutix Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI in NPDR

First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI's registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global ...
Verywell Health

We Asked a Doctor How to Balance Your Blood Sugar With Every Meal

Discover how to plan balanced meals with carbs, protein, and healthy fats to prevent blood sugar spikes and crashes.
The Manila Times

Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

The SCS Microinjector is a proven in-office, repeatable, non-surgical procedure for the targeted delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and ...
The Manila Times

Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR

First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative diabetic retinopathy (NPDR) ...